


EMLc

ATC codes: **L01CB01**

| | |
|--------------------------|--|
| Indication | Hodgkin lymphoma ICD11 code: 2C10.Z |
| INN | Etoposide |
| Medicine type | Chemical agent |
| List type | Complementary (EML) (EMLc) |
| Formulations | Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule ; 100 mg in vial powder for injection (as phosphate) Oral > Solid: 100 mg capsule ; 50 mg capsule |
| EML status history | First added in 2015 (TRS 994) Changed in 2019 (TRS 1021) Changed in 2023 (TRS 1049) |
| Sex | All |
| Age | Also recommended for children |
| Therapeutic alternatives | The recommendation is for this specific medicine |
| Patent information | Patents have expired in most jurisdictions Read more about patents .  |

Tags

Cancer

Wikipedia

[Etoposide](#) 

DrugBank

[Etoposide](#) 

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the inclusion of an additional dose form of etoposide (Powder for injection: 100 mg (as phosphate) in vial) to the EML and EMLc.

Expert Committee report 

